Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04343287 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment
A Phase 2 study of Dry Eye Syndrome, sponsored by BRIM Biotechnology.
- Completed
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
- 4
- Study locations
NCT04343287 is a Phase 2 study of Dry Eye Syndrome that has completed, run by BRIM Biotechnology. The registered enrollment target is 220 participants, above the 143-participant average among 10 other Dry Eye Syndrome trials with a reported enrollment target (54% higher). The trial reports 4 study locations across 4 states.
The verdict
NCT04343287, a Phase 2 study of Dry Eye Syndrome, has completed, sponsored by BRIM Biotechnology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
- 4
- Study locations
Study Summary
The objective of this study is to compare the safety and efficacy of BRM421 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BRM421
Study Locations (4)
California
- Eye Research Foundation - Newport Beach
Indiana
- Midwest Cornea Associates, LLC - Indianapolis
Massachusetts
- Andover Eye Associates - Andover
Tennessee
- Total Eye Care - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2020-01-15 |
| Est. Completion | 2020-06-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04343287
The ClinicalTrials.gov registry entry for NCT04343287 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 143-participant average among 10 other Dry Eye Syndrome trials with a reported enrollment target (54% higher). The listed sponsor is BRIM Biotechnology, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Eye Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04343287 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Indiana, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04343287 about?
NCT04343287 is a clinical study titled "Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment". The objective of this study is to compare the safety and efficacy of BRM421 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.
What is the current status of trial NCT04343287?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2020-01-15. Estimated completion is 2020-06-23.
What conditions does trial NCT04343287 study?
This clinical trial studies the following conditions: Dry Eye Syndrome.
What interventions are being tested in trial NCT04343287?
The interventions under investigation include: Placebo (DRUG), BRM421 (DRUG).
Who is sponsoring clinical trial NCT04343287?
This trial is sponsored by BRIM Biotechnology, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04343287 being conducted?
This trial has 4 study locations across California, Indiana, Massachusetts, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye
COMPLETED · Phase 2
-
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)
RECRUITING · Phase 1
-
Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome
COMPLETED · NA
-
Study of SkQ1 as Treatment for Dry-eye Syndrome
COMPLETED · Phase 3
-
Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease
COMPLETED · Phase 1
-
Effects of Dry Eye Treatments on the Ocular Surface
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.